DD23 Biomarker: a prospective clinical assessment in routine urinary cytology specimens from patients being monitored for TCC.

Background: A prospective clinical study was conducted to assess the ability of the DD23 murine monoclonal antibody to enhance detection of bladder cancer in routine alcohol fixed urine cytology samples.

Methods: Prospectively, 308 bladder cytology specimens were obtained from patients with a history of bladder cancer with a mean age of 71.4+/-11.